174 related articles for article (PubMed ID: 37104245)
1. Combating castration-resistant prostate cancer by co-targeting the epigenetic regulators EZH2 and HDAC.
Schade AE; Kuzmickas R; Rodriguez CL; Mattioli K; Enos M; Gardner A; Cichowski K
PLoS Biol; 2023 Apr; 21(4):e3002038. PubMed ID: 37104245
[TBL] [Abstract][Full Text] [Related]
2. Combining EZH2 and HDAC inhibitors to target castration-resistant prostate cancers.
Coulter JB; Easwaran H
PLoS Biol; 2023 Apr; 21(4):e3002081. PubMed ID: 37104249
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM
Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193
[TBL] [Abstract][Full Text] [Related]
4. DNMT1-mediated epigenetic silencing of TRAF6 promotes prostate cancer tumorigenesis and metastasis by enhancing EZH2 stability.
Li Z; Li B; Yu H; Wang P; Wang W; Hou P; Li M; Chu S; Zheng J; Mao L; Bai J
Oncogene; 2022 Aug; 41(33):3991-4002. PubMed ID: 35804015
[TBL] [Abstract][Full Text] [Related]
5. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
[TBL] [Abstract][Full Text] [Related]
6. Dual targeting of EZH2 and androgen receptor as a novel therapy for castration-resistant prostate cancer.
Shankar E; Franco D; Iqbal O; Moreton S; Kanwal R; Gupta S
Toxicol Appl Pharmacol; 2020 Oct; 404():115200. PubMed ID: 32805266
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer.
Bai Y; Zhang Z; Cheng L; Wang R; Chen X; Kong Y; Feng F; Ahmad N; Li L; Liu X
J Biol Chem; 2019 Jun; 294(25):9911-9923. PubMed ID: 31085587
[TBL] [Abstract][Full Text] [Related]
8. LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer.
Wang D; Ding L; Wang L; Zhao Y; Sun Z; Karnes RJ; Zhang J; Huang H
Oncotarget; 2015 Dec; 6(38):41045-55. PubMed ID: 26516927
[TBL] [Abstract][Full Text] [Related]
9. A Novel Role of Silibinin as a Putative Epigenetic Modulator in Human Prostate Carcinoma.
Anestopoulos I; Sfakianos AP; Franco R; Chlichlia K; Panayiotidis MI; Kroll DJ; Pappa A
Molecules; 2016 Dec; 22(1):. PubMed ID: 28042859
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress.
Liao Y; Chen CH; Xiao T; de la Peña Avalos B; Dray EV; Cai C; Gao S; Shah N; Zhang Z; Feit A; Xue P; Liu Z; Yang M; Lee JH; Xu H; Li W; Mei S; Pierre RS; Shu S; Fei T; Duarte M; Zhao J; Bradner JE; Polyak K; Kantoff PW; Long H; Balk SP; Liu XS; Brown M; Xu K
Proc Natl Acad Sci U S A; 2022 Jan; 119(3):. PubMed ID: 35031563
[TBL] [Abstract][Full Text] [Related]
11. SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer.
Lu W; Liu S; Li B; Xie Y; Izban MG; Ballard BR; Sathyanarayana SA; Adunyah SE; Matusik RJ; Chen Z
Oncogene; 2017 Mar; 36(10):1364-1373. PubMed ID: 27869166
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer.
Chen H; Tu SW; Hsieh JT
J Biol Chem; 2005 Jun; 280(23):22437-44. PubMed ID: 15817459
[TBL] [Abstract][Full Text] [Related]
13. Dual-Acting Peptides Target EZH2 and AR: A New Paradigm for Effective Treatment of Castration-Resistant Prostate Cancer.
Han Z; Rimal U; Khatiwada P; Brandman J; Zhou J; Hussain M; Viola RE; Shemshedini L
Endocrinology; 2022 Nov; 164(1):. PubMed ID: 36288553
[TBL] [Abstract][Full Text] [Related]
14. Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
McLeod AB; Stice JP; Wardell SE; Alley HM; Chang CY; McDonnell DP
Prostate; 2018 Mar; 78(4):266-277. PubMed ID: 29243324
[TBL] [Abstract][Full Text] [Related]
15. Green tea-induced epigenetic reactivation of tissue inhibitor of matrix metalloproteinase-3 suppresses prostate cancer progression through histone-modifying enzymes.
Deb G; Shankar E; Thakur VS; Ponsky LE; Bodner DR; Fu P; Gupta S
Mol Carcinog; 2019 Jul; 58(7):1194-1207. PubMed ID: 30854739
[TBL] [Abstract][Full Text] [Related]
16. Involvement of aberrantly activated HOTAIR/EZH2/miR-193a feedback loop in progression of prostate cancer.
Ling Z; Wang X; Tao T; Zhang L; Guan H; You Z; Lu K; Zhang G; Chen S; Wu J; Qian J; Liu H; Xu B; Chen M
J Exp Clin Cancer Res; 2017 Nov; 36(1):159. PubMed ID: 29141691
[TBL] [Abstract][Full Text] [Related]
17. EZH2 dependent H3K27me3 is involved in epigenetic silencing of ID4 in prostate cancer.
Chinaranagari S; Sharma P; Chaudhary J
Oncotarget; 2014 Aug; 5(16):7172-82. PubMed ID: 25115397
[TBL] [Abstract][Full Text] [Related]
18. BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
Gorodetska I; Lukiyanchuk V; Peitzsch C; Kozeretska I; Dubrovska A
Int J Cancer; 2019 Dec; 145(11):2974-2985. PubMed ID: 30968962
[TBL] [Abstract][Full Text] [Related]
19. EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers.
Au SL; Wong CC; Lee JM; Wong CM; Ng IO
PLoS One; 2013; 8(6):e68226. PubMed ID: 23826380
[TBL] [Abstract][Full Text] [Related]
20. Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors.
Huang X; Yan J; Zhang M; Wang Y; Chen Y; Fu X; Wei R; Zheng XL; Liu Z; Zhang X; Yang H; Hao B; Shen YY; Su Y; Cong X; Huang M; Tan M; Ding J; Geng M
Cell; 2018 Sep; 175(1):186-199.e19. PubMed ID: 30220457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
